Preparing manuscripts or conference abstracts
Last updated
Was this helpful?
Last updated
Was this helpful?
Here we describe how to cite FinnGen, if you are preparing a manuscript based on FinnGen data.
Note, similar practices should be implemented prior to the submission of abstracts to conferences where the results of your work are from FinnGen data.
When drafting a manuscript using FinnGen data (note this does not apply ), please familiarize yourself with the documentation below and add the relevant parts to your manuscript. Please familiarize yourself also to
When you are about to submit a manuscript or conference abstract containing FinnGen results, it needs to first be circulated to the FinnGen Scientific Committee for review and feedback. Provide the following information to FinnGen admin team via email ().
Manuscripts:
Manuscript files (all files, including supplements)
The target journal's title
The target submission date
Contact person for comments
Conference abstracts:
Abstract file (all files, including supplements)
Name of the conference you are aiming to attend
The target submission date
Contact person for comments
The admin team will pass the manuscript/abstract to the FinnGen Scientific Committee. Manuscript circulation time is three weeks, which should be reserved for the to give feedback. Abstract circulation time is one week.
In case you need to provide email or street address for the authors, you can use these for 'FinnGen':
email: finngen-info@helsinki.fi
Street address: Biomedicum Helsinki 2U, P.O.Box 20 (Tukholmankatu 8)
If you need to describe FinnGen study in your manuscript/abstract here is an overall description you can modify for the use:
“FinnGen (https://www.finngen.fi/en) launched in 2017, is a public-private research project, combining genome and digital healthcare data on about 500,000 Finns. The nation-wide research project aims to provide novel medically and therapeutically relevant insight into human diseases. FinnGen is a pre-competitive partnership of Finnish biobanks and their background organizations (universities and university hospitals) and international pharmaceutical industry partners and Finnish biobank cooperative (FINBB). All FinnGen partners are listed here: https://www.finngen.fi/en/partners.”
Please don’t copy the text above directly, on our website or in the FinnGen 'flagship' paper to avoid any copyright issues.
Include to your manuscript the general ethics statement paragraph and permit numbers. Note that permit numbers are updated per each Data Freeze.
FinnGen ethics statements
FinnGen samples were genotyped with ThermoFisher, Illumina and Affymetrix arrays.
From Data Freeze 8 on we have used SisuV4 imputation panel.
General documentation on the genotype processing and QC and GWAS analyses (the content may need to be adjusted depending on the Data Freeze/Release used).
In case you use FinnGen core analysis results in your manuscript (GWAS, fine-mapping, co-localization etc.) the analysis details are described in the Data Freeze/Release specific analysis reports. You can also use the General documentation available here.
Some journals may ask you to provide data access statement.
In a nutshell:
Based on National and European regulations (GDPR) access to individual-level sensitive health data must be approved by national authorities for specific research projects and for specifically listed and approved researchers.
The health data used and generated in FinnGen are provided by the National Health Register Authorities including Finnish Institute of Health and Welfare, Statistics Finland, KELA, Digital and Population Data Services Agency and approved, either by the individual authorities or by the Finnish Data Authority, Findata, for purposes of FinnGen project. Therefore the project cannot grant access to individual-level data to others.
Please note:
The genotype data for the FinnGen releases are returned to the biobanks after the 1-year exclusivity period to the FinnGen consortium members.
FinnGen should be listed as one of the authors in manuscripts that are mostly based on FinnGen data and approved . Please use ‘FinnGen’ as the author, not ’FinnGen Consortium’, ‘FinnGen Study’ or any other variation of this, even if you see those used in other publications.
When you add 'FinnGen' as an author you often need to provide the list of FinnGen consortium members (so called ‘’) as a supplementary file. Note that the ‘’ is updated periodically - so make sure to include the newest version to your submission. Usually the individuals in the banner are not PubMed indexed but this depends on the journal policy. The FinnGen banner is not needed if FinnGen data is only used for replication analyses, in that case we ask you add FinnGen in the Acknowledgements. Please refer to to see how FinnGen should appear in the manuscripts.
You can also use the general description of the project on
You can also cite so-called Please note that the 'flagship' paper is based on FinnGen Data Freeze 5 results and some methods may have changed since.
FinnGen utilizes biobank samples that consist of: 1) prospective samples (‘new samples’) and 2) . 'New samples' are collected by request to give a voluntary biobank consent and to donate a biobank sample (typically blood). Hospital biobank and Terveystalo Biobank samples are typically collected during diagnostic sampling at hospital laboratories or at the ward. Blood Service Biobank consenting and sampling occurs in conjunction of blood donation. THL Biobank consenting and sampling typically occurs in conjunction with collection of research samples. On the other hand, legacy samples are older sample cohorts that have been collected for a specific research project before the Finnish Biobank Act came into effect (September 2013). These old research cohorts have then been transferred to a biobank according to the Finnish Biobank Act 13 §.
Read more about FinnGen sample DNA isolation protocols.
The ‘new samples’ were genotyped with FinnGen ThermoFisher Axiom custom array at the ThermoFisher genotyping service in San Diego, CA, US. More information (including array content) about the FinnGen custom array can be found .
The ‘legacy samples’ were genotyped over the years using various generations of Illumina and Affymetrix GWAS arrays. Read more about legacy samples from .
The genotype data were imputed with a . Genotype imputation process is described .
Genotype data processing from Data Freeze 7 onward is described in detail .
You can also check out the analysis on our public website. Note that the content may need to be adjusted depending on the Data Freeze/Release used.
can be cited by adding the webpage link
Please make sure to include in the acknowledgements all FinnGen Partners and funding organizations. The up to date list of parties to be acknowledged available . Please note that these are updated periodically, so make sure to use the newest version available.
Please refer to the Data Availability section of the as an example for drafting the data access/availability statement in your manuscript."
Any researcher can apply for the health register data from the Finnish Data Authority Findata () and for individual-level genotype data from Finnish biobanks via the Fingenious portal () hosted by the Finnish Biobank Cooperative FINBB ().
We encourage you to publish your article also on an open access publishing platform. Especially, University of Helsinki affliated researchers should see the instructions for (green open access).
We encourage you . After doing so, you can easily . While many FinnGen summary statistics are available in public services such as the GWAS Catalogue, we prefer that FinnGen community researchers publish their summary statistics in our public bucket.
FinnGen core analysis summary statistics from each data release will be made publicly available after and can be accessed freely from: www.finngen.fi/en/access_results.